A premier Saudi investment firm boasts a diverse portfolio that spans multiple asset classes, including real assets and alternative investments. Over the past decade, the investment firm has evolved into one of the region’s most compelling success stories, driven by a steadfast commitment to delivering value, fostering partnerships, and catalyzing sustainable development. Their vision is to become a leading integrated solutions provider in cell and gene therapy in Saudi Arabia, establishing themselves as the first globally trusted partner in precision medicine within the Middle East. The firm focus on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5-10M. The firm aims to act as a catalyst for developing this vital industry and emphasize the importance of the private sector in supporting emerging, innovative sectors. Their aspiration is to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases in the region. The firm is committed to contributing to the localization of the biotechnology industry as part of the global system and building national expertise to achieve these ambitious goals.
Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1 and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For Tech-Driven Biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development.
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve out or partnership in the region is necessary.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
The FDA’s Center for Devices and Radiological Health (aka CDRH aka the folks who approve med devices) had firings a little more than a week ago, continuing from the layoffs at the NIH and CDC. Early signs indicate a reduction of 10% – 15%. Those who lost their jobs included those funded by medical device user fees and not tax-payer dollars. Since the cuts affected probationary employees the most, recent hires to evaluate newer technologies like AI-assisted imaging and digital health are gone, making it hard to imagine approvals for these modalities would not grind to a halt. AdvaMed’s head, Scott Whitaker, conveyed that AdvaMed had sent a letter to HHS in response, emphasizing the importance of AI and related technologies, the patient-facing effects throwing a wrench in the approval machine would have, and the lack of tax-payer savings. This may have been effective, as in breaking news today, the Associated Press reported that some of the fired individuals received calls and messages reversing their dismissals, stating terminations were “rescinded effective immediately.”
Next Phase Newsletter 